ASSORTMENT CHARACTERISTICS OF PROSTATOPROTECTORS, REGISTERED IN UKRAINE, THE REPUBLIC OF POLAND AND THE REPUBLIC OF BELARUS

Abstract

The purpose of the work. Studying the peculiarities of the assortment formation of medicines for the prostatitis treatment in Ukraine, Poland and Belarus.

Materials and Methods. Materials of research were the data of the official resources of medicine registration in Ukraine, Poland and Belarus dated 01.08.2017. Methods of research – systematic, statistic, comparing analysis, ranking and generalization.

Results and Discussion.  It was found out that Ukraine has wider assortment (1.3 times) of the trade names of prostatitis protectors than Belarus, though twice less than Poland, Germany, India, Italy and the Netherlands are the leaders among the foreign state traders in Ukraine. As to Poland, such state leaders are Germany, Great Britain, the Netherlands and France. Only two countries – Ukraine and Russia are the trade leaders in the Republic of Belarus. In each of these countries there are only nine registrated prostatitis protectors manufacturers out of 30, to be more exact in Germany, Italy, the Netherlands, Hungary, Poland, Spain, Romania, Slovenia and the Czech Republic. The most part of all the assortment of registered trade names of prostatitis protectors in Ukraine and Poland belongs to the antagonists alfa-adrenoreceptors, though in Belarus there are medications that are used while benign hypertrophy of prostate gland. The research shows that the usage of contract forms while entering the markets of countries under study is possible. The existence of high dependence of prostatitis protectors on import was also demonstrated. It is states that only nine out of 10 trade names of prostatitis protectors in medical forms for oral application were registered, all the rest are just suppositories and parenteral medical forms. However, in the Polish market only prostatitis protectors in medical forms for oral application are used. Speaking about Belarus more than four fifth of trade names for prostatitis protectors are presented in the medical form of oral application and the tenth part is represented by the suppositories, all the rest – by parenteral medical forms.

Conclusions. Having analyzed the data of the official registration list of medicines in Ukraine, Poland and Belarus dated 01.08.2017 special and similar characteristics of these state markets were defined due to the assortment of prostatitis protectors, structure of their manufacturers and applicants, forms of market entering, assortment dependence upon the import and the kind of medical forms. All the results lay the foundation for further forming of assortment policy as to prostatitis protectors in Ukraine.